crystal, pharmaceutical composition, jak2 tyrosine kinase inhibitor, and therapeutic agent for polycythemia vera.

摘要

the main purpose of the present invention is to provide new maleate crystals of (s) -n2- [1- (4-fluorophenyl) ethyl] -4- (1-methyl-1h-pyrazol-4-yl) -n6- (pyrazine -2-yl) pyridine-2,6-diamine (hereinafter compound a). a type i crystal of compound a, showing diffraction peaks at diffraction angles (2¿) of 6.9 degrees, 9.4 degrees, 12.5 degrees, 15.1 degrees, 16.4 degrees, 18.3 degrees , 19.0 degrees, 24.9 degrees, 25.4 degrees, 27.3 degrees and 27.7 degrees in the X-ray diffraction spectrum in the powder obtained using cuka radiation (¿= 1.54 å). a type ii crystal of compound a exhibiting diffraction peaks at the diffraction angles (2¿) of 6.9 degrees, 9.2 degrees, 12.4 degrees, 14.8 degrees, 16.5 degrees, 18.1 degrees, 18.5 degrees, 19.8 degrees, 23.6 degrees, 24.9 degrees and 27.7 degrees in the X-ray diffraction spectrum in the powder obtained using cuka radiation (¿= 1.54 å).